Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.

Cell cycle (Georgetown, Tex.) - 1 Nov 2020

Li Zhenqing, Xue Qun, Xu Jianxun, Zhang Pengfei, Ding Bo

Abstract excerpt

RBM10 is the RNA-binding protein often absent or mutated in lung adenocarcinoma, rendering it as a potential biomarker or even therapeutic target to prolongate survival time. In this study, we investigated the involvement of RBM10 mutation in the pathogenesis and tumorigenesis of lung adenocarcinoma and identified the differentials in relative signal pathways, aiming to provide the new therapeutic approaches. By...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Alternative Splicing
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Lung Neoplasms

Share to Prognosis

Share to RNA-Binding Proteins

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 33064970
DOI: 10.1080/15384101.2020.1829801
PMCID: PMC7714495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.PMID 33064970Read ↗

Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinomaSemantic proximity Read ↗

RBM10, a New Regulator of p53Semantic proximity Read ↗

RBM10 Interacts with CTBNNBIP1 and Represses Lung Adenocarcinoma Progression Through the Wnt/β- catenin PathwaySemantic proximity Read ↗

RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.Semantic proximity Read ↗

Differences in Genetics and Microenvironment of Lung Adenocarcinoma Patients with or without TP53 MutationSemantic proximity Read ↗

RBM10: Structure, functions, and associated diseases.Semantic proximity Read ↗

Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinomaSemantic proximity Read ↗

RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.Semantic proximity Read ↗

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.Semantic proximity Read ↗

RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.Semantic proximity Read ↗

Significance of TP53 Mutation in Cellular Process and Disease Progression in Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.